



Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

Telix Pharmaceuticals enters into Exclusive Licence Agreement with Osaka University

Melbourne (Australia) and Osaka (Japan) – 27th April 2020. Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') today announces it has concluded an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry technology.

The licensed technology is the outcome of a research collaboration established between Telix and Osaka University in 2018 to develop second-generation variants of TLX101 (¹³¹I-IPA) that may be suitable for certain advanced cancer therapy applications. The newly developed radiochemistry enables the production of TLX101 with high production efficiency as well as astatine-211 (²¹¹At) variants, which may be suitable for other cancer indications. The research collaboration that led to the IP creation was jointly funded over a two year period by Telix and a grant from the Japan Science and Technology Agency (JST) through its Open Innovation Platform with Enterprises, Research Institutes and Academia (OPERA) program.

Astatine-211 (²¹¹At), a high-energy alpha emitter is a promising radioisotope for the development of new molecularly targeted radiation (MTR) drugs, due its very short range in tissue (a few cells deep) and its minimal effect on healthy tissues adjacent to cancer cells.

President of Telix Japan, Dr Shintaro Nishimura said, "This novel radiochemistry is a very significant result from the OPERA program and I believe that Osaka University is very well placed to lead the clinical evaluation of astatinated radiopharmaceuticals in the future. I wish to acknowledge Prof Hatazawa, Dr. Shirakami and their colleagues at Osaka University, and the ongoing support from JST through the OPERA program. Together, we are making good progress towards the clinical evaluation of this technology in Japan for the benefit of patients globally".

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telix.com.

About the Institute for Radiation Science (IRS), Osaka University

The Institute for Radiation Sciences, Osaka University was launched in 2018 to integrate radiation-related research and facilities on a university-wide basis, to foster new cross disciplinary radiation science research. The institute aims to foster the peaceful use of radiation based on industry-academia-government co-creation, by enhancement and rationalization of the university-wide system for radiation safety management and functional improvement of educational research in the field of radiation. For more information visit www.irs.osaka-u.ac.jp

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations

Dr David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.